More on McKesson (MCK): Q2 earnings beat estimates, but more importantly, the company raises its...

|About: McKesson Corporation (MCK)|By:, SA News Editor

More on McKesson (MCK): Q2 earnings beat estimates, but more importantly, the company raises its FY12 earnings forecast. With one of the lowest PEG ratio's on the NYSE for a U.S. drug wholesaler, investors are more keenly focused on its foward guidance than any other metric at present. Shares are flat AH.